Plexus (NASDAQ: PLXS) announced today its partnership with Quidel Corporation (“Quidel”) in support of the Sofia®2 Fluorescent Immunoassay Analyzer. Plexus will provide Supply Chain and Manufacturing Solutions to Quidel, an industry leader in diagnostic healthcare. The two companies will collaborate to scale the Sofia®2 product in order to support increased demand for point-of-care testing used in the fight against COVID-19.
Sofia®2 is Quidel’s best-selling cartridge-based rapid diagnostic system for infectious disease testing. It is a small bench top analyzer that can be used near patients and in laboratory settings. Sofia® 2 has the power to deliver fast, highly accurate, objective and automated results, in 15 minutes or less, that aid in the diagnosis of many critical diseases and conditions, including: COVID-19, Influenza A+B, Strep A, Lyme Disease and Respiratory Syncytial Virus (RSV).
Todd Kelsey, Plexus’ President and Chief Executive Officer, commented, “We are delighted to partner with Quidel as we support the expanding production needs of the Sofia® 2 system. Plexus’ vision is to help create the products that build a better world. Our direct involvement in the fight against COVID-19, as a result of this exciting partnership, helps us fulfill this vision. Plexus will leverage our tenured expertise in the Healthcare/Life Sciences sector to support Quidel in providing this critical product to healthcare providers. Our experience in highly complex products and demanding regulatory environments, coupled with our commitment to exceptional quality and operational execution, uniquely qualifies Plexus to support this effort.”
Douglas Bryant, President and Chief Executive Officer of Quidel Corporation, commented, “We are pleased to partner with Plexus and welcome another ally in the fight against COVID-19. Our collaboration allows us to secure a critical aspect of our supply chain. Plexus has the ability to manufacture our Sofia® 2 instruments reliably and at scale, which allows us to achieve our objective of doing the most good by expanding highly accurate, affordable, point-of-care testing in the communities we serve.”
Source: Company Press Release
